What's Going On With CNS Pharmaceuticals Stock Tuesday?
What's Going On With CNS Pharmaceuticals Stock Tuesday?
A multicenter Phase 1 study of TPI 287 combined with bevacizumab in recurrent GBM patients showed a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 13.4 months. In comparison, bevacizumab alone or with chemotherapy showed a PFS of 2-4 months and an OS of 6-9 months.CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares traded higher initially Tuesday morning but have since reversed following the company's announcement that it entered into an exclusive license agreement with Cortice Biosciences.
CNS Pharmaceuticals公司（纳斯达克股票代码：CNSP）的股票周二早上最初上涨，但在公司宣布与Cortice Biosciences签订独家许可协议后出现回调。
The Details: CNS secured an exclusive license and the intellectual property rights for TPI 287, a potential treatment for glioblastoma multiforme (GBM).
细节：CNS获得了TPI 287的独家许可和知识产权，这是一种治疗根治性多形性胶质母细胞瘤（GBM）的潜在疗法。
CNS will pay Cortice 616, 698 shares of the company's common stock in exchange for the license and intellectual property rights. In addition, there are possible future success-dependent milestone payments of cash or the company's common stock
CNS将向Cortice支付616,698股公司普通股以换取许可和知识产权。此外，还有可能基于未来成就而支付现金或公司普通股的里程碑款项。
A multicenter Phase 1 study of TPI 287 combined with bevacizumab in recurrent GBM patients showed a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 13.4 months. In comparison, bevacizumab alone or with chemotherapy showed a PFS of 2-4 months and an OS of 6-9 months.
TPI 287联合贝伐单抗治疗复发性GBM的多中心1期研究显示，无进展生存期(PFS)为5.5个月，总生存期(OS)为13.4个月。相比之下，贝伐单抗单独或联合化疗的PFS为2-4个月，OS为6-9个月。
CNS believes that another one of its drug candidates for the treatment of GBM, Berubicin, could serve as an ideal complementary asset to TPI 287.
CNS认为，其治疗GBM的另一种药物候选者Berubicin可以作为TPI 287的理想补充资产。
John Climaco, CEO of CNS Pharmaceuticals, stated, "For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease."
CNS Pharmaceuticals的首席执行官John Climaco表示：“多年来，我们的团队一直在寻找另一个药物候选者，在GBm方面具有与Berubicin相同的高水平的人体数据支持的治疗潜力。内部许可TPI 287是迈向变革性的重要一步，我们已准备好执行我们的愿景，使CNS Pharmaceuticals成为开发治疗这种可怕且目前无法逃脱致命疾病的生物制药公司的领先企业。”
The company intends to consult with the U.S. FDA to receive feedback on the design of a study aimed at registering TPI 287 for recurrent GBM, with plans to start the study in 2025.
该公司打算与美国FDA咨询，以获得有关设计旨在注册TPI 287用于复发性GBm的研究的反馈意见，并计划在2025年开始该研究。
Related Link: Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
相关链接：专家展望：14位分析师看Sage Therapeutics
CNSP Price Action: At the time of publication, CNS shares are trading 60% lower at 41 cents, per data from Benzinga Pro.
CNS公司(CNS)股价在发布时下跌了60%，收于41美分，根据Benzinga Pro的数据。
Image: Myriams-Fotos from Pixabay
图片：来自Pixabay的Myriams-Fotos
.
.
